Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine
Posted: 1 June 2020 | GenScript | No comments yet
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
Given this drastic statistic, researchers are developing personalised immunotherapies that, as opposed to one-size-fits-all approaches, train a patient’s immune system to attack and kill their own cancerous tissue based on individualised tumour biomarkers known as neoantigens. Unlike common tumour-associated antigens, neoantigens are only expressed in cancer and are therefore highly immunogenic.
Related topics
Biomarkers, Drug Development, Immunotherapy, Peptide Therapeutics, Therapeutics
Related organisations
GenScript